0 (0%) | 02-13 05:07 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 6.67 | 1-year : | 8.23 |
Resists | First : | 5.71 | Second : | 7.05 |
Pivot price | 5.1 ![]() |
|||
Supports | First : | 3.54 | Second : | 2.95 |
MAs | MA(5) : | 4.76 ![]() |
MA(20) : | 4.95 ![]() |
MA(100) : | 0 | MA(250) : | 0 | |
MACD | MACD : | -0.9 ![]() |
Signal : | -1.1 ![]() |
%K %D | K(14,3) : | 29.2 ![]() |
D(3) : | 31.5 ![]() |
RSI | RSI(14): 34.1 ![]() |
|||
52-week | High : | 50.81 | Low : | 3.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RADX ] has closed above bottom band by 22.0%. Bollinger Bands are 0% narrower than normal.
If tomorrow: | Open lower | Open higher |
High: | 5.09 - 5.13 | 5.13 - 5.16 |
Low: | 4.56 - 4.6 | 4.6 - 4.63 |
Close: | 4.58 - 4.65 | 4.65 - 4.69 |
Mon, 10 Feb 2025
Clinical Trial Breakthrough: RADX's RAD 101 Outperforms in Brain Metastases Detection Study - StockTitan
Thu, 06 Feb 2025
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Wed, 27 Nov 2024
Radiopharm Achieves Nasdaq Listing of American Depositary Shares - GlobeNewswire
Fri, 08 Nov 2024
Novel Microdevices, Inc. Announces ~$2.7M Follow on Funding from NIH RADx® Tech - PR Web
Tue, 08 Oct 2024
Healgen Scientific Receives FDA De Novo Marketing Authorization for At-Home COVID-19 and Influenza Test - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 2,330 (M) |
Shares Float | 1,580 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 1.1 (%) |
Shares Short | 4 (K) |
Shares Short P.Month | 9 (K) |
EPS | -0.08 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.05 |
Profit Margin | 0 % |
Operating Margin | 771.8 % |
Return on Assets (ttm) | -30.1 % |
Return on Equity (ttm) | -131.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -0.01 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.02 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -23 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -58 |
PEG Ratio | 0 |
Price to Book value | 77.33 |
Price to Sales | 5515.91 |
Price to Cash Flow | -470.47 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |